Combinational Targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma

Molecular Therapy

Volumn 21, Issue 11, 2013, Pages 2087-2101

  Hegde, Meenakshi ^a,b   Corder, Amanda ^a,b   Chow, Kevin Kh ^a,b   Mukherjee, Malini ^b   Ashoori, Aidin ^a,b   Kew, Yvonne ^c   Zhang, Yi Jonathan ^c   Baskin, David S ^c   Merchant, Fatima A ^d   Brawley, Vita S ^a,b   Byrd, Tiara T ^a,b   Krebs, Simone ^a,b   Wu, Meng Fen ^a,b   Liu, Hao ^a,b   Heslop, Helen E ^a,b   Gottachalk, Stephen ^a,b   Yvon, Eric ^e   Ahmed, Nabil ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF HOUSTON   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 13 RECEPTOR ALPHA2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER PATIENT; CELL KILLING; CHIMERIC ANTIGEN RECEPTOR T LYMPHOCYTE; CONTROLLED STUDY; DONOR; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MALE; MATHEMATICAL MODEL; MOUSE; MULTICOLOR FLOW CYTOMETRY; NONHUMAN; PROTEIN TARGETING; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR ELIMINATION; TUMOR IMMUNITY; TUMOR XENOGRAFT;

MURINAE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HEK293 CELLS; HUMANS; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; MICE; MICE, SCID; MODELS, BIOLOGICAL; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; TUMOR ESCAPE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887471195     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.185     Document Type: Article

References (46)

1. Stupp, R, Mason, WP, van den Bent, MJ, Weller, M, Fisher, B, Taphoorn, MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
2. Stupp, R, Hegi, ME, Mason, WP, van den Bent, MJ, Taphoorn, MJ, Janzer, RC et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466.
3. Porter, DL, Levine, BL, Kalos, M, Bagg, A and June, CH (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733.
4. Pule, MA, Savoldo, B, Myers, GD, Rossig, C, Russell, HV, Dotti, G et al. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14: 1264-1270.
5. Grupp, SA, Kalos, M, Barrett, D, Aplenc, R, Porter, DL, Rheingold, SR et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368: 1509-1518.
6. Brentjens, RJ, Davila, ML, Riviere, I, Park, J, Wang, X, Cowell, LG et al. (2013). CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapyrefractory acute lymphoblastic leukemia. Sci Transl Med 5: 177ra38.
7. Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2. 1-11, 2013.
8. Study of Administration of CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM (HERT-GBM). 1-6, 2011.
9. White Blood Cells With Anti-EGFR-III for Malignant Gliomas. 1-11-0013.
10. Dunn, GP, Old, LJ and Schreiber, RD (2004). The three Es of cancer immunoediting. Annu Rev Immunol 22: 329-360.
11. Nagaraj, S, Gupta, K, Pisarev, V, Kinarsky, L, Sherman, S, Kang, L et al. (2007). Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 13: 828-835.
12. Leen, AM, Rooney, CM and Foster, AE (2007). Improving T cell therapy for cancer. Annu Rev Immunol 25: 243-265.
13. Zhang, JG, Eguchi, J, Kruse, CA, Gomez, GG, Fakhrai, H, Schroter, S et al. (2007). Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cellbased therapeutics. Clin Cancer Res 13(2 Pt 1): 566-575.
14. Liang, Y, Diehn, M, Watson, N, Bollen, AW, Aldape, KD, Nicholas, MK et al. (2005). Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA 102: 5814-5819.
15. Okada, H, Low, KL, Kohanbash, G, McDonald, HA, Hamilton, RL and Pollack, IF (2008). Expression of glioma-associated antigens in pediatric brain stem and nonbrain stem gliomas. J Neurooncol 88: 245-250.
16. Liu, G, Ying, H, Zeng, G, Wheeler, CJ, Black, KL and Yu, JS (2004). HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 64: 4980-4986.
17. Jarboe, JS, Johnson, KR, Choi, Y, Lonser, RR and Park, JK (2007). Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res 67: 7983-7986.
18. Wykosky, J, Gibo, DM, Stanton, C and Debinski, W (2005). EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 3: 541-551.
19. Wykosky, J, Gibo, DM, Stanton, C and Debinski, W (2008). Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res 14: 199-208.
20. Kahlon, KS, Brown, C, Cooper, LJ, Raubitschek, A, Forman, SJ and Jensen, MC (2004). Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 64: 9160-9166.
21. Chan, AC, Iwashima, M, Turck, CW and Weiss, A (1992). ZAP-70: a 70 kd proteintyrosine kinase that associates with the TCR zeta chain. Cell 71: 649-662.
22. Isakov, N, Wange, RL, Burgess, WH, Watts, JD, Aebersold, R and Samelson, LE (1995). ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: the tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity. J Exp Med 181: 375-380.
23. Jensen, MC, Popplewell, L, Cooper, LJ, DiGiusto, D, Kalos, M, Ostberg, JR et al. (2010). Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 16: 1245-1256.
24. Park, JR, Digiusto, DL, Slovak, M, Wright, C, Naranjo, A, Wagner, J et al. (2007). Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 15: 825-833.
25. Brentjens, RJ, Rivière, I, Park, JH, Davila, ML, Wang, X, Stefanski, J et al. (2011). Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118: 4817-4828.
26. Ahmed, N, Salsman, VS, Kew, Y, Shaffer, D, Powell, S, Zhang, YJ et al. (2010). HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res 16: 474-485.
27. Ahmed, N, Ratnayake, M, Savoldo, B, Perlaky, L, Dotti, G, Wels, WS et al. (2007). Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res 67: 5957-5964.
28. Ahmed, N, Salsman, VS, Yvon, E, Louis, CU, Perlaky, L, Wels, WS et al. (2009). Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther 17: 1779-1787.
29. Rainusso, N, Brawley, VS, Ghazi, A, Hicks, MJ, Gottschalk, S, Rosen, JM et al. (2012). Immunotherapy targeting HER2 with genetically modified T cells eliminates tumorinitiating cells in osteosarcoma. Cancer Gene Ther 19: 212-217.
30. Guess, HA and Thomas, JE (1990). A rapidly converging algorithm for exact binomial confidence intervals about the relative risk in follow-up studies with stratified incidence-density data. Epidemiology 1: 75-77.
31. Chow, KK, Naik, S, Kakarla, S, Brawley, VS, Shaffer, DR, Yi, Z et al. (2013). T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther 21: 629-637.
32. Weijtens, ME, Hart, EH and Bolhuis, RL (2000). Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Ther 7: 35-42.
33. Morgan, RA, Yang, JC, Kitano, M, Dudley, ME, Laurencot, CM and Rosenberg, SA (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18: 843-851.
34. Dudley, ME, Wunderlich, JR, Robbins, PF, Yang, JC, Hwu, P, Schwartzentruber, DJ et al. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
35. Heslop, HE and Rooney, CM (1997). Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev 157: 217-222.
36. Hoyos, V, Savoldo, B and Dotti, G (2012). Genetic modification of human T lymphocytes for the treatment of hematologic malignancies. Haematologica 97: 1622-1631.
37. Nakazawa, Y, Huye, LE, Salsman, VS, Leen, AM, Ahmed, N, Rollins, L et al. (2011). PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther 19: 2133-2143.
38. Manuri, PV, Wilson, MH, Maiti, SN, Mi, T, Singh, H, Olivares, S et al. (2010). piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther 21: 427-437.
39. Quintarelli, C, Vera, JF, Savoldo, B, Giordano Attianese, GM, Pule, M, Foster, AE et al. (2007). Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 110: 2793-2802.
40. Di Stasi, A, Tey, SK, Dotti, G, Fujita, Y, Kennedy-Nasser, A, Martinez, C et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365: 1673-1683.
41. Straathof, KC, Spencer, DM, Sutton, RE and Rooney, CM (2003). Suicide genes as safety switches in T lymphocytes. Cytotherapy 5: 227-230.
42. Straathof, KC, Pulè, MA, Yotnda, P, Dotti, G, Vanin, EF, Brenner, MK et al. (2005). An inducible caspase 9 safety switch for T-cell therapy. Blood 105: 4247-4254.
43. Wilkie, S, van Schalkwyk, MC, Hobbs, S, Davies, DM, van der Stegen, SJ, Pereira, AC et al. (2012). Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol 32: 1059-1070.
44. Kloss, CC, Condomines, M, Cartellieri, M, Bachmann, M and Sadelain, M (2013). Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 31: 71-75.
45. Madhankumar, AB, Mintz, A and Debinski, W (2004). Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2. Neoplasia 6: 15-22.
46. Kong, S, Sengupta, S, Tyler, B, Bais, AJ, Ma, Q, Doucette, S et al. (2012). Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res 18: 5949-s5960.